Company News & Publications

Publications

 

Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements

Tamás Solymosi, Zsolt Ötvös, Betti Ordasi, Tamás Jordán, Sándor Semsey, László Molnár, Soma Ránky, Genovéva Filipcsei, Gábor Heltovics, Hristos Glavinas //Int J Pharm. 2017 Sep 15;532(1):427-434.

» Read publication

 

Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect

Tamás Solymosi, Zsolt Ötvös, Réka Angi, Betti Ordasi, Tamás Jordán, László Molnár, John McDermott, Vanessa Zann, Ann Churc, Stuart Mair, Genovéva Filipcsei, Gábor Heltovics, Hristos Glavinas //Cancer Chemother Pharmacol. 2017 Aug 3.

» Read publication

 

Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method

Tamás Solymosi, Réka Angi, Orsolya Basa-Dénes, Soma Ránky , Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei  and Gábor Heltovics //Eur J Pharm Biopharm. 2015 Aug;94:135-40.

» Read publication

 

Novel Continuous flow technology for the development of nanostructured Aprepitant formulation with improved pharmacocinetics properties

Réka Angi, Tamás Solymosi, Zsolt Ötvös, Betti Ordasi, Hristos Glavinas, Genovéva Filipcsei, Gábor Heltovics and Ferenc Darvas //Eur J Pharm Biopharm. 2014 Apr;86(3):361-8.

» Read publication

 

Flow chemistry for nanotechnology, Flow chemistry graduate textbook, Chapter 6, Vol.2.: Applications,  Ed. by Darvas, Ferenc / Hessel, Volker / Dorman, György, Walter de Gruyter, 2014, pp 161-187

Genovéva Filipcsei, Zsolt Ötvös, Réka Angi and Ferenc Darvas

» Read publication

 

News & Press releases

 

DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company's novel Super-API technology platform

MSIDA, Malta, Oct. 05, 2017 - DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA.

» Read more



DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

19th December 2016, Swatar, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib – a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). 

» Read more



 

Dr. Philip Kantoff - leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor

14th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program.

» Read more



 

DRGT’s novel Abiraterone Acetate composition – an opportunity for dose reduction and increased efficacy in prostate cancer

9th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration-resistant prostate cancer.

» Read more



 

Quotient Clinical begins prostate cancer project for Druggability Technologies

June 23, 2015 - Quotient Clinical, the Translational Pharmaceutics® Company, initiates a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate.

» Read more



Druggability Technologies enters into a strategic collaboration with Bayer HealthCare

DRGT signs a broad collaboration agreement with Bayer HealthCare to leverage DRGT’s Super-API Technology to accelerate the discovery and development of novel drugs.

» Read more